{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:02:28Z","timestamp":1791928948465,"version":"4.3.4"},"reference-count":51,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"4","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest. Ophthalmol. Vis. Sci."],"published-print":{"date-parts":[[2026,4,2]]},"DOI":"10.1167\/iovs.67.4.4","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T14:30:46Z","timestamp":1775140246000},"page":"4","source":"Crossref","is-referenced-by-count":0,"title":["Identification of Brimonidine as a Novel Substrate of Organic Cation Transporters OCT2 and MATE1 Expressed in Human Eye"],"prefix":"10.1167","volume":"67","author":[{"given":"Charlotte","family":"K\u00f6lz","sequence":"first","affiliation":[{"name":"Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, and University of T\u00fcbingen, T\u00fcbingen, Germany"},{"name":"Department of Clinical Pharmacology, University of T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Neul","sequence":"additional","affiliation":[{"name":"Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, and University of T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Hofmann","sequence":"additional","affiliation":[{"name":"Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, and University of T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia C.","family":"Dressler","sequence":"additional","affiliation":[{"name":"Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, and University of T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"S\u00fcsskind","sequence":"additional","affiliation":[{"name":"Institute for Ophthalmic Research, Center for Ophthalmology, University of T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Wissinger","sequence":"additional","affiliation":[{"name":"Institute for Ophthalmic Research, Center for Ophthalmology, University of T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schwab","sequence":"additional","affiliation":[{"name":"Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, and University of T\u00fcbingen, T\u00fcbingen, Germany"},{"name":"Department of Clinical Pharmacology, University of T\u00fcbingen, T\u00fcbingen, Germany"},{"name":"Department of Pharmacy and Biochemistry, University of T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne T.","family":"Nies","sequence":"additional","affiliation":[{"name":"Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, and University of T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/bjo.2005.081224","article-title":"The number of people with glaucoma worldwide in 2010 and 2020","volume":"90","author":"Quigley","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"bib2","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis","volume":"121","author":"Tham","year":"2014","journal-title":"Ophthalmology"},{"key":"bib3","doi-asserted-by":"publisher","first-page":"13762","DOI":"10.1038\/s41598-021-92971-w","article-title":"Prevalence of primary open angle glaucoma in the last 20 years: a meta-analysis and systematic review","volume":"11","author":"Zhang","year":"2021","journal-title":"Sci Rep"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"749858","DOI":"10.3389\/fphar.2021.749858","article-title":"Topical medication therapy for glaucoma and ocular hypertension","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"key":"bib5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1080\/14656566.2018.1544241","article-title":"Brimonidine tartrate for the treatment of glaucoma","volume":"20","author":"Oh","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"bib6","first-page":"1","article-title":"European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition","volume":"105","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jtos.2023.05.012","article-title":"Impact of glaucoma medications on the ocular surface and how ocular surface disease can influence glaucoma treatment","volume":"29","author":"Kolko","year":"2023","journal-title":"Ocul Surf"},{"key":"bib8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jtos.2022.07.007","article-title":"Topical glaucoma medications\u2014clinical implications for the ocular surface","volume":"26","author":"Fineide","year":"2022","journal-title":"Ocul Surf"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2147\/tcrm.2006.2.4.337","article-title":"Brimonidine in the treatment of glaucoma and ocular hypertension","volume":"2","author":"Cantor","year":"2006","journal-title":"Ther Clin Risk Manage"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jtos.2023.08.001","article-title":"Molecular nature of ocular surface barrier function, diseases that affect it, and its relevance for ocular drug delivery","volume":"30","author":"Kaur","year":"2023","journal-title":"Ocul Surf"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1007\/s13346-024-01756-x","article-title":"Recent updates on drug delivery approaches for improved ocular delivery with an insight into nanostructured drug delivery carriers for anterior and posterior segment disorders","volume":"15","author":"Khan","year":"2025","journal-title":"Drug Deliv Transl Res"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s11095-008-9694-0","article-title":"Recent perspectives in ocular drug delivery","volume":"26","author":"Gaudana","year":"2009","journal-title":"Pharm Res"},{"key":"bib13","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1167\/iovs.09-4290","article-title":"The prostaglandin transporter OATP2A1 is expressed in human ocular tissues and transports the antiglaucoma prostanoid latanoprost","volume":"51","author":"Kraft","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"suppl 1","key":"bib14","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0039-6257(02)00302-8","article-title":"Ocular and systemic pharmacokinetics of latanoprost in humans","volume":"47","author":"Sj\u00f6quist","year":"2002","journal-title":"Surv Ophthalmol"},{"key":"bib15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.addr.2017.12.009","article-title":"Expression, activity and pharmacokinetic impact of ocular transporters","volume":"126","author":"Vellonen","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"bib16","doi-asserted-by":"publisher","first-page":"108268","DOI":"10.1016\/j.pharmthera.2022.108268","article-title":"Hepatic solute carrier transporters and drug therapy: regulation of expression and impact of genetic variation","volume":"238","author":"Nies","year":"2022","journal-title":"Pharmacol Ther"},{"key":"bib17","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1124\/pr.118.015578","article-title":"Organic cation transporters in health and disease","volume":"72","author":"Koepsell","year":"2020","journal-title":"Pharmacol Rev"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1208\/s12248-013-9465-7","article-title":"Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney","volume":"15","author":"Motohashi","year":"2013","journal-title":"AAPS J"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/cpt.1098","article-title":"Influence of transporter polymorphisms on drug disposition and response: a perspective from the International Transporter Consortium","volume":"104","author":"Yee","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"bib20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41573-023-00877-1","article-title":"Membrane transporters in drug development and as determinants of precision medicine","volume":"23","author":"Galetin","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"bib21","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.3109\/02713683.2016.1143013","article-title":"PTGFR and SLCO2A1 gene polymorphisms determine intraocular pressure response to latanoprost in Han Chinese patients with glaucoma","volume":"41","author":"Zhang","year":"2016","journal-title":"Curr Eye Res"},{"key":"bib22","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1007\/s40123-023-00794-x","article-title":"Patient factors influencing intraocular penetration of brimonidine-related eye drops in adults: a post hoc pooled analysis","volume":"12","author":"Kunikane","year":"2023","journal-title":"Ophthalmol Ther"},{"key":"bib23","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1111\/bph.15370","article-title":"Characterization of CYP2D6 drugs as substrates of human organic cation transporters (OCTs) and multidrug and toxin extrusion proteins (MATEs)","volume":"178","author":"Neul","year":"2021","journal-title":"Br J Pharmacol"},{"key":"bib24","doi-asserted-by":"publisher","first-page":"e22163","DOI":"10.1371\/journal.pone.0022163","article-title":"Proton pump inhibitors inhibit metformin uptake by organic cation uptake transporters (OCTs)","volume":"6","author":"Nies","year":"2011","journal-title":"PLoS One"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/clpt.2011.165","article-title":"A common 5\u2019-UTR variant in MATE2-K is associated with poor response to metformin","volume":"90","author":"Choi","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"bib26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/0003-2697(85)90442-7","article-title":"Measurement of protein using bicinchoninic acid","volume":"150","author":"Smith","year":"1985","journal-title":"Anal Biochem"},{"key":"bib27","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00210-007-0219-x","article-title":"Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1)","volume":"376","author":"Nies","year":"2008","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"bib28","doi-asserted-by":"publisher","first-page":"106941","DOI":"10.1016\/j.phrs.2023.106941","article-title":"Novel drug transporter substrates identification: an innovative approach based on metabolomic profiling, in silico ligand screening and biological validation","volume":"196","author":"Nies","year":"2023","journal-title":"Pharmacol Res"},{"key":"bib29","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/clpt.2013.81","article-title":"In vitro methods to support transporter evaluation in drug discovery and development","volume":"94","author":"Brouwer","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"bib30","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/FPC.0b013e32832cc7e9","article-title":"Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin","volume":"19","author":"Chen","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"bib31","first-page":"870","article-title":"Functional characterization of organic cation drug transport in the pigmented rabbit conjunctiva","volume":"41","author":"Ueda","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib32","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1167\/iovs.05-0189","article-title":"Characterization of brimonidine transport in retinal pigment epithelium","volume":"47","author":"Zhang","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib33","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41597-021-00908-9","article-title":"The transcriptome of wild-type and immortalized corneal epithelial cells","volume":"8","author":"Furuya","year":"2021","journal-title":"Sci Data"},{"key":"bib35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/978-3-642-14541-4","article-title":"Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy","volume":"201","author":"Nies","year":"2011","journal-title":"Handb Exp Pharmacol"},{"key":"bib36","doi-asserted-by":"publisher","first-page":"12403","DOI":"10.1021\/acs.jmedchem.2c01075","article-title":"Substrates and inhibitors of the organic cation transporter 3 and comparison with OCT1 and OCT2","volume":"65","author":"Gebauer","year":"2022","journal-title":"J Med Chem"},{"key":"bib37","doi-asserted-by":"publisher","first-page":"7232","DOI":"10.1021\/jm400966v","article-title":"Identification of novel substrates and structure activity relationship of cellular uptake mediated by the human organic cation transporters 1 and 2 (hOCT1 and hOCT2)","volume":"56","author":"Hendrickx","year":"2013","journal-title":"J Med Chem"},{"key":"bib38","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1515\/hsz-2016-0236","article-title":"Tropane alkaloids as substrates and inhibitors of human organic cation transporters of the SLC22 (OCT) and the SLC47 (MATE) families","volume":"398","author":"Chen","year":"2017","journal-title":"Biol Chem"},{"key":"bib39","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1124\/dmd.116.074708","article-title":"Interaction and transport of methamphetamine and its primary metabolites by organic cation and multidrug and toxin extrusion transporters","volume":"45","author":"Wagner","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"bib40","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1021\/acs.jcim.8b00466","article-title":"Integrative data mining, scaffold analysis, and sequential binary classification models for exploring ligand profiles of hepatic organic anion transporting polypeptides","volume":"59","author":"T\u00fcrkov\u00e1","year":"2018","journal-title":"J Chem Inf Model"},{"key":"bib41","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"bib42","first-page":"253","article-title":"Molecular basis of polyspecific drug and xenobiotic recognition by OCT1 and OCT2","volume":"72","author":"Suo","year":"2023","journal-title":"Nat Struct Mol Biol"},{"key":"bib43","doi-asserted-by":"publisher","first-page":"9444","DOI":"10.1038\/s41467-025-64490-z","article-title":"Structural basis of drug recognition by human MATE1 transporter","volume":"16","author":"Romane","year":"2025","journal-title":"Nat Commun"},{"key":"bib44","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1097\/01.ASN.0000019413.78751.46","article-title":"cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney","volume":"13","author":"Urakami","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"bib45","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.bcp.2007.04.010","article-title":"Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions\/H(+)-organic cation antiporters","volume":"74","author":"Tanihara","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"bib46","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1124\/dmd.108.023762","article-title":"Functional characterization of the human organic cation transporter 2 variant p.270Ala>Ser","volume":"37","author":"Zolk","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"bib47","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1021\/acs.molpharmaceut.6b00937","article-title":"Identification and characterization of trimethylamine-N-oxide uptake and efflux transporters","volume":"14","author":"Teft","year":"2017","journal-title":"Mol Pharm"},{"key":"bib48","doi-asserted-by":"publisher","first-page":"F1669","DOI":"10.1152\/ajprenal.00422.2019","article-title":"Molecular and cellular physiology of organic cation transporter 2","volume":"317","author":"Wright","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"key":"bib49","doi-asserted-by":"publisher","first-page":"120924","DOI":"10.1016\/j.ijpharm.2021.120924","article-title":"Drug delivery to the anterior segment of the eye: a review of current and future treatment strategies","volume":"607","author":"Mofidfar","year":"2021","journal-title":"Int J Pharm"},{"key":"bib50","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1002\/cpt.2605","article-title":"Regulation of drug transport proteins\u2014from mechanisms to clinical impact; a white paper on behalf of the ITC","volume":"112","author":"Brouwer","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"bib51","doi-asserted-by":"publisher","first-page":"eaal2439","DOI":"10.1126\/scitranslmed.aal2439","article-title":"Comment on \"Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin.\"","volume":"9","author":"Winter","year":"2017","journal-title":"Sci Transl Med"},{"key":"bib34","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/978-3-319-23793-0_3","article-title":"Pharmacological and toxicological significance of the organic cation transporters OCT and MATE: drug disposition, interaction and toxicity","volume-title":"Organic Cation Transporters","author":"Motohashi","year":"2016"}],"container-title":["Investigative Ophthalmology & Visual Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/iovs.arvojournals.org\/article.aspx?doi=10.1167\/iovs.67.4.4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:32:19Z","timestamp":1791927139000},"score":1,"resource":{"primary":{"URL":"http:\/\/iovs.arvojournals.org\/article.aspx?doi=10.1167\/iovs.67.4.4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1167\/iovs.67.4.4","relation":{},"ISSN":["1552-5783"],"issn-type":[{"value":"1552-5783","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,2]]}}}